Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

4.490 -0.140 (-3.02%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Taysha Gene Therapies, Inc. (TSHA) Q3 2021 Earnings Call Transcript ↗

November 11, 2021

TSHA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 10, 2021

From Taysha Gene Therapies

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences

November 08, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10

November 03, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Analyst Ratings For Taysha Gene Therapies ↗

August 18, 2021

Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst rat...

Via Benzinga

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement Approach Demonstrating Therapeutic Potential for The Treatment of Angelman Syndrome in the Journal JCI Insight

October 25, 2021

From Taysha Gene Therapies

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit

October 21, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence

October 13, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome

October 12, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batten Hope

October 05, 2021

From Taysha Gene Therapies

Via Business Wire

Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis

September 29, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences

September 28, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome

September 22, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods & Clinical Development

September 15, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome

September 08, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences

September 01, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha's Rare Epilepsy Gene Therapy Receives European Orphan Drug Tag ↗

August 25, 2021

The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc's (NASDAQ: TSHA) TSHA-105, AAV9-based gene therapy for SLC13A5-...

Via Benzinga

Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission

August 25, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 17, 2021

Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock increased by 25.72% to $2.59 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

August 17, 2021

Tuesday morning, 282 companies set new 52-week lows. Key Facts: Alibaba Group Holding (NYSE:BABA) was the biggest company by market cap to set a new 52-week low....

Via Benzinga

Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease

August 17, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies, Inc. (TSHA) Q2 2021 Earnings Call Transcript ↗

August 16, 2021

TSHA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development ↗

August 16, 2021

Taysha Gene Therapies Inc (NASDAQ: TSHA) has entered into a loan and security agreement with Silicon Valley Bank (SVB), providing up to $100 million of...

Via Benzinga

Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 16, 2021

From Taysha Gene Therapies

Via Business Wire

Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing

August 16, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16

August 09, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences

August 02, 2021

From Taysha Gene Therapies, Inc.

Via Business Wire

Earnings Scheduled For August 16, 2021 ↗

August 16, 2021

Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.